Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/12168
Title: Temporal trajectory of B-type natriuretic peptide in patients with CKD stages 3 and 4, dialysis, and kidney transplant.
Authors: Roberts, Matthew A;Hare, David L;Sikaris, Ken;Ierino, Francesco L
Affiliation: and.
Department of Renal Medicine, Eastern Health Clinical School, Monash University, Victoria, Australia
Department of Cardiology, and.
Department of Medicine, University of Melbourne, Victoria, Australia
Matthew.Roberts@easternhealth.org.au.
Melbourne Pathology Service, Collingwood, Victoria, Australia
Department of Nephrology, Austin Health, Victoria, Australia
Issue Date: 10-Apr-2014
Citation: Clinical Journal of the American Society of Nephrology : Cjasn 2014; 9(6): 1024-32
Abstract: B-type natriuretic peptide (BNP) concentration predicts outcome in patients undergoing dialysis. Because survival and cardiovascular risk change across the CKD continuum, serial changes in BNP were compared in patients at different CKD stages and after kidney transplantation.Patients with CKD stages 3 and 4 (CKD 3-4), dialysis patients, and kidney transplant recipients (KTRs) from one center had two measurements of BNP taken a median of 161 days apart in 2003-2004 and were followed until July 2012. Both BNP-32 (Triage BNP; Biosite Diagnostics) and NT-BNP-76 (proBNP; Roche Diagnostics) were assayed. The interaction between change in log-transformed BNP concentration over time and patient group was tested by fitting regression models on panel data with random effects. Survival after the second measurement was compared by tertile of change in BNP.Patients with CKD 3-4 (n=48), dialysis patients (n=102), and KTRs (n=73) were followed for a median of 5.7, 4.8, and 5.9 years, respectively. The interaction between patient group and BNP measurements over time was significant for NT-BNP-76 (P<0.001) and BNP-32 (P<0.01). Median NT-BNP-76 increased in dialysis patients and those with CKD 3-4 from 3850 pg/ml (interquartile range [IQR], 1776-12,323 pg/ml) to 18,830 pg/ml (IQR, 6114-61,009 pg/ml; P<0.001) and from 698 pg/ml (IQR, 283-2922 pg/ml) to 2529 pg/ml (IQR, 347-9277 pg/ml; P=0.002), respectively. Change was not significant for KTRs or comparisons made with BNP-32. Survival rate was significantly lower for patients with the highest tertile of change in NT-BNP-76 among patients with CKD 3-4 (P=0.02), but not in the dialysis or KTR groups. In 11 patients who received a kidney transplant during the study, median NT-BNP-76 decreased from 9607 pg/ml (IQR, 2292-31,282 pg/ml) to 457 pg/ml (IQR, 203-863 pg/ml) after transplant (P<0.01).The temporal trajectory of BNP differs between dialysis patients and those with CKD 3-4 and KTRs. This has important implications for the development of BNP-guided management strategies in CKD.
Internal ID Number: 24721887
URI: http://ahro.austin.org.au/austinjspui/handle/1/12168
DOI: 10.2215/CJN.08640813
URL: http://www.ncbi.nlm.nih.gov/pubmed/24721887
Type: Journal Article
Subjects: B-type natriuretic peptide
cardiovascular disease
chronic kidney disease
dialysis
kidney transplant
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.